Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial

Liver Transplantation

Volumn 6, Issue 3, 2000, Pages 277-286

  Mitzner, Steffen R ^b   Stange, Jan ^b   Klammt, Sebastian ^b   Risler, Teut ^a   Erley, Christiane M ^a   Bader, Brigitte D ^a   Berger, Elke D ^a   Lauchart, Werner ^b   Peszynski, Piotr ^b   Freytag, Jens ^b   Hickstein, Heiko ^b   Loock, Jan ^b   Löhr, Johannes Mathias ^b   Liebe, Stefan ^b   Emmrich, Jörg ^b   Korten, Gero ^b   Schmidt, Reinhard ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE;

ADULT; ANION EXCHANGE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSATE; HEMODIALYSIS; HEPATORENAL SYNDROME; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL;

EID: 0034109694     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/lv.2000.6355     Document Type: Article

References (39)

1. Arroyo V, Ginès P. Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis. Gastroenterology 1992;102:1077-1079.
2. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105: 229-236.
3. Epstein M. Hepatorenal syndrome. In: Epstein M (ed). The kidney in liver disease (ed 4). Philadelphia: Hanley & Belfus, 1996:75-108.
4. Earley LE. Presentation of diagnostic criteria of the hepatorenal syndrome. In: Bartoli E, Chiandussi L (eds). Hepatorenal syndrome. Padova: Piccin Medical, 1979:495-504.
5. Epstein M. Hepatorenal syndrome: Emerging perspectives. Semin Nephrol 1997;17:563-575.
6. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-176.
7. Gentilini P, La Villa G, Casini-Raggi V, Romanelli RG. Hepatorenal syndrome and its treatment today. Eur J Gastroenterol Hepatol 1999;11:1061-1065.
8. Bataller R, Arroyo V, Gines P, Sort P. Hepatorenal syndrome. Forum (Genova) 1998;8:62-81.
9. Eckardt KU. Renal failure in liver disease. Intensive Care Med 1999;25:5-14.
10. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998;28:937-943.
11. Brensing KA, Perz J, Sauerbruch T. TIPS in hepatorenal syndrome. In: Arroyo V, Bosch J, Bruguera M, Rodés J, Sánchez Tapias JM (eds). Treatment of liver disease. Barcelona: Masson, 1999:53-59.
12. Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 1998;28:416-422.
13. Wong F. Transjugular intrahepatic portosystemic stent shunt for hepatorenal syndrome and ascites. Digestion 1998;59(suppl 2):S41-S44.
14. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29:1690-1697.
15. Gulberg V, Luppa P, Pauletzki J, Paumgartner G, Gerbes AL. Successful conservative therapy of hepatorenal syndrome with vasopressin I receptor antagonist ornipressin. Z Gastroenterol 1998;36:1053-1058.
16. Ganne-Carrie N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci 1996;41:1054-1056.
17. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870-875.
18. Eisenman A, Armali Z, Enat R, Bankir L, Baruch Y. Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. J Intern Med 1999;246:183-190.
19. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-570.
20. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transsection of the esophagus for bleeding esophageal varices. Br J Surg 1973;60:646-649.
21. Rossle M, Siegerstetrer V, Huber M, Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): State of the art. Liver 1998;18:73-89.
22. Kaplan AA, Epstein M. Extracorporeal blood purification in the management of patients with hepatic failure. Semin Nephrol 1997;17:576-582.
23. Hughes RD, Courtney JM. Dialysis/adsorption techniques for acute liver failure. In: Lee W, Williams R (eds). Acute liver failure. Cambridge: Cambridge University Press, 1997:278-284.
24. Awad SS, Rich PB, Kolla S, Younger JG, Reickert CA, Downing VP, Bartlett RH. Characteristics of an albumin dialysate hemodiafiltration system for the clearance of unconjugated bilirubin. ASAIO J 1997;43:M745-M749.
25. Rahman TM, Hodgson HJF. Review article: Liver support systems in acute hepatic failure. Aliment Pharmacol Ther 1999;13:1255-1272.
26. Kreymann B, Seige M, Schweigart U, Kopp KF, Classen M. Albumin dialysis: Effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: A new possibility for the elimination of protein-bound toxins. J Hepatol 1999;31:1080-1085.
27. Stange J, Mitzner S, Risler T, Erley CM, Lauchart W, Goehl H, et al. Molecular adsorbent recirculating system (MARS) - Clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-330.
28. Seige M, Kreymann B, Jeschke B, Schweigart U, Kopp KF, Classen M. Long-term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Transplant Proc 1999;31:1371-1375.
29. Mitzner S, Stange J, Klammt S, Peszynski P, Risler T, Schmidt R. Albumin dialysis "MARS." Clinical results in extracorporeal treatment of hepatorenal syndrome [abstract]. Hepatology 1999;30(suppl):S418A.
30. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.
31. Gentilini P. Hepatorenal syndrome and ascites - An introduction. Liver 1999;19:5-14.
32. Salerno F, Borroni G, Moser P, Badalamenti S, Cassara L, Maggi A, et al. Survival and prognostic factors of cirrhosis patients with ascites: A study of 134 outpatients. Am J Gastroenterol 1993;88:514-519.
33. United Network for Organ Sharing: Policy 3.6: Organ distribution/3.6.4. Degree of medical urgency (25.6.99). Available at: www.unos.org. Accessed March 24, 2000.
34. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patient’s blood and a bioartificial liver. Int J Artif Organs 1996;19:677-691.
35. Awad SS, Sawada S, Soldes OS, Rich PB, Klein R, Alarcon WH, Bartlett RH. Can the clearance of tumor necrosis factor-alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? ASAIO J 1999;45:47-49.
36. Loock J, Peters E, Stange J, Mitzner S, Peszynski P, Klammt S, et al. Change of human serum amino acid patterns (Fischer index) during a new dialysis treatment for liver failure (MARS) [abstract]. Int J Artif Organs 1997;20:500A.
37. Watanabe FD, Mullon CJP, Hewitt WR, Rozga J, Solomon B, Demetriou AA. Clinical experiences with a bioartificial liver in the treatment of severe liver failure. Ann Surg 1997;225:484-494.
38. Keller F, Heinze H, Jochimsen F, Paßfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): The role of hemodialysis. Ren Fail 1995;17:135-146.
39. Perez GO, Golper TA, Epstein M, Oster JR. Dialysis, hemofiltration, and other extracorporeal techniques in the treatment of the renal complications of liver disease. In: Epstein M (ed). The kidney in liver disease (ed 4). Philadelphia: Hanley & Belfus, 1996:517-528.